Savara Inc. (NASDAQ:SVRA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Savara Inc. (NASDAQ:SVRA) have been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $9.1250.

Several research firms recently commented on SVRA. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Wednesday, October 8th. Lifesci Capital raised shares of Savara to a “strong-buy” rating in a research note on Tuesday, October 14th. Wells Fargo & Company raised their target price on Savara from $7.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, December 18th. Citizens Jmp cut their price target on Savara from $11.00 to $10.00 and set a “market outperform” rating for the company in a research note on Thursday, November 13th. Finally, Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. VR Adviser LLC raised its position in Savara by 172.7% during the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after acquiring an additional 5,626,624 shares during the period. Bain Capital Life Sciences Investors LLC increased its stake in shares of Savara by 20.8% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company’s stock worth $48,754,000 after purchasing an additional 3,035,164 shares in the last quarter. Frazier Life Sciences Management L.P. raised its position in shares of Savara by 32.4% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company’s stock worth $31,751,000 after purchasing an additional 2,801,922 shares during the last quarter. Rosalind Advisors Inc. lifted its stake in Savara by 50.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock valued at $14,280,000 after buying an additional 1,345,056 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in Savara in the 3rd quarter valued at about $3,014,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Trading Down 0.5%

Shares of NASDAQ:SVRA opened at $6.44 on Wednesday. Savara has a 12-month low of $1.89 and a 12-month high of $7.01. The company has a market capitalization of $1.31 billion, a PE ratio of -12.15 and a beta of 0.23. The business has a 50 day moving average of $5.06 and a two-hundred day moving average of $3.64. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.32.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). As a group, analysts forecast that Savara will post -0.45 EPS for the current year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.